- $485.88m
- $260.49m
Neurogene Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Neurogene Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Brief: Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies
Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Neurogene Q3 Net Income USD -20.217 Million
Neurogene drops after pausing part of gene therapy study due to serious side effect
U.S. RESEARCH ROUNDUP-Cable One, Neurogene, Topbuild
Brief: Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome
Neurogene not to proceed with gene therapy for Batten disease; shares drop
Brief: Neurogene Announces Oversubscribed $200 Mln Private Placement
Neurogene Inc reports results for the quarter ended in June - Earnings Summary
Brief: Neurogene Q2 Net Income USD -18.492 Million
Neurogene Inc expected to post a loss of $1.05 a share - Earnings Preview
Brief: Neurogene Announces First Patient Dosed In Gene Therapy Clinical Trial For Rett Syndrome
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
Neurogene Inc reports results for the quarter ended in March - Earnings Summary
Brief: Neurogene Q1 Net Income USD -16.921 Million
Neurogene Inc expected to post a loss of $1.14 a share - Earnings Preview
Brief: Neurogene Announces Upcoming Presentation Of Safety Data From Phase 1/2 Trial Of NGN-401 Gene Therapy